The drug for the treatment of prostate cancer Rakurs (223Ra), developed by specialists of the Federal Medical and Biological Agency, is registered in Russia

The drug destroys bone metastases, enabling a person diagnosed with prostate cancer to prolong their life against the background of the disease, the agency explained. In addition, it affects the pain syndrome and makes it possible to stop using painkillers.

@russia_seichass